Where’s your place in the CMO hierarchy?
Find out in the CMO industry’s authoritative analysis of manufacturing of NDA approvals. This CMO scorecard was compiled through hundreds of professional hours of research and analysis, and is presented in a 40-page report with over 30 graphs and tables. Only CMO Scorecard enables the CMO industry to benchmark its performance over time, and CMOs to benchmark their performance against the industry.
Our research team crunched the numbers on 2016 drug approvals authorized by FDA’s CDER, CBER, Fast Track and Breakthrough drugs, and selected EMA approved drugs. For the first time, we are including information on the location of outsourced dose manufacturing facilities.
Reasons to buy
This report is required reading for –
– CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
– Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
Table of Content: Key Points
NDA Approvals Overview
US vs. EU Approval Performance
Outsourced Dose Manufacture
Special Product Categories
Outsourcing by Global Bio/Pharma Companies
Outsourced Dose Form
Manufacture by Country
Outsourced API Approvals
What It Means
Note on Methodology
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch: